A Phase 1 Open-Label, Parallel-Design, Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide in Participants With Normal and Impaired Renal Function
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
View MoreAge
18 Years - 79 Years
Sex
All
Healthy Volunteers
Accepts Healthy Volunteers
Medical Condition
Chronic Hepatitis D Infection
Gender
N/A
Date
March 2023 - May 2026
Study Type
Interventional
Study Phase
Phase 1
Product
Bulevirtide (BLV)
Edgewater, Florida, United States, 32132
Miami Lakes, Florida, United States, 33014
Miami Lakes, Florida, United States, 33016
Miami, Florida, United States, 33014
Miami, Florida, United States, 33147
Saint Petersburg, Florida, United States, 33705
Tampa, Florida, United States, 33603
Saint Paul, Minnesota, United States, 55114
Share Trial